Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

Pharmacogenetics

Volumn 13, Issue 10, 2003, Pages 619-626

  Kirchheiner, Julia ^a,d   Klein, Christian ^a   Meineke, Ingolf ^b   Sasse, Johanna ^a   Zanger, Ulrich M ^c   Mürdter, Thomas E ^c   Roots, Ivar ^a   Brockmöller, Jürgen ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Bupropion; CYP2B6; Cytochrome P450; Hydroxybupropion; Polymorphism

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CYTOCHROME P450 2B6; HYDROXYBUPROPION; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BUPROPION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYLATION; MALE; METABOLIC CLEARANCE RATE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0142188754     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200310000-00005     Document Type: Article

References (31)

1. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56:395-401.
2. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 1992; 7:7-14.
3. Ferris RM, Cooper BR, Maxwell RA. Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry 1983; 44:74-78.
4. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc 1994; 69:1069-1081.
5. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002; 288: 1260-1264.
6. Chapman SC, Jamrozik K. Is bupropion (Zyban) causing deaths? Med J Aust 2002; 176:134.
7. Wooltorton E. Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. J Can Med Assoc 2002; 166:68.
8. Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983; 44:79-81.
9. Laizure SC, DeVane CL, Stewart JT, Dommisse CS, Lai AA. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 1985; 38:586-589.
10. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28:1176-1183.
11. Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 2001; 29:1123-1129.
12. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28:1222-1230.
13. Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ, et al. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996; 26:1155-1166.
14. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53:5629-5637.
15. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002; 54:157-167.
16. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996; 59:613-623.
17. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, et al. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 2001; 51:281-285.
18. Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996; 278:21-30.
19. Ward BA, Gorski CJ, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDs therapy and utility of efavirenz as substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287-300.
20. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 1997; 25:985-993.
21. Miksys S, Lerman C, Shields P, Mash D, Tyndale R. The influence of smoking, alcoholism an genetics on CYP2B6 in human brain. Clin Pharmacol Ther 2003; 73:P59.
22. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11:399-415.
23. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48:409-415.
24. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
25. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269:15419-15422.
26. Lai AA, Schroeder DH. Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry 1983; 44:82-84.
27. Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA Jr, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 2001; 41:770-778.
28. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997; 37:737-743.
29. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003; 31:398-403.
30. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003; 3:53-61.
31. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y, Kamataki T. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 2001; 281:1256-1260.